Avivagen, Inc. · OTC:VIVXF
Avivagen — Investor Presentation (September 2020)
19 slides from Avivagen's investor presentation, September 2020
Slide 1: Kym Anthony, CEO, September 2020
KYM ANTHONY, C.E.O. SEPTEMBER, 2020 VIV:TSXV VIVXF:OTCQB 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain forward-looking statements that are based upon current expectations of management, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements conta
Slide 3: Our OxC-beta Product
OUR OxC-beta™ PRODUCT What it is: • Oxidized Beta Carotene Technology Properties: Discovered at • Supports Immune Defenses the National • Reduces Inflammation Research OxC-beta was Discovered, NOT Counsel Created • Published Ubiquity Paper 3
Slide 4: Our Business Model Is to Focus on 3 Discrete Markets
OUR BUSINESS MODEL IS TO FOCUS ON 3 DISCRETE MARKETS: OxC-beta™ OxC-beta™ OxC-beta™ For For For Livestock Companion Animal Human Applications: Nutraceutical 201 Each Represents a Tremendous Global Market Opportunity 4
Slide 5: OxC-beta for Livestock Feed
OxC-beta™ FOR LIVESTOCK FEED Tonnes per year 1B of feedstock Access to global feed market through >30% current distribution agreements Massive Market Opportunity 5
Slide 6: Up to 80% of All Antibiotics Are Used as AGPs
UP TO 80% Of all Antibiotics are used as AGP’s 2006 2017 2019 2020 EU-wide ban on FDA bans use of Chick-Fil-A China all AGP’s antibiotics considered reaches 5- year announces “medically important” for goal to go NAE country-wide ban animal weight gain of AGP’s by July 2020 6
Slide 7: Antibiotic Resistance a Global Threat
Antibiotic Resistance a Global Threat 2M Infections Antibiotic resistance has potential to 700,000 $100T create more Deaths AMR could cost the economic damage globe up to $100 Trillion by 2050 than the 2008 $10k–$40k financial crisis More per hospital stay Massive Health and Economic Implications 7
Slide 8: Competitive Products
COMPETITIVE PRODUCTS Probiotics/Prebiotics: • Mixed efficacy, storage requirements OxC-beta™ Essential Oils: Represents a • Old Technology, mixed efficacy, Next Generation compliance difficulties Antibiotic Zinc Oxide: Alternative • Environmental issues, Banned in many countries 8
Slide 9: Product Sales
Product Sales UNAHCO: 18.1 tonnes purchased to date for swine; recently added poultry MEXICO: 1st order March 2020 for 250 kgs, later increased to 2 tonnes BRAZIL: Received approval June 2020, 1st sale August 2020 9
Slide 10: Product Sales
Product Sales TAIWAN: 1st order October 2019, repeated monthly sales since THAILAND: 1st order September 2018, repeated monthly sales since MALAYSIA: 1st customer order December 2019 10
Slide 11: Recent Developments
Recent Developments BRAZIL: 3rd largest livestock feed market @69 mm tonnes, approved June 2020, distribution agreement with Look Chemicals, 1st sale August 2020 NEW ZEALAND: Very successful dairy trial with NZ Dairy Associationsales interest growing COFCO BIOTECH: Agreement to assist VIV with appro
Slide 12: Mexican Market Offers Significant Potential
Mexican market offers significant potential • Two very positive tests of the use of OxC-beta™ Livestock in commercial dairy production 36 mm tonne • Initial 350 kg order increased to 2 tonnes, with ongoing annual market purchase discussions continuing with Melder and other producers • Serious discus
Slide 13: Testing Proves Efficacy and Safety
Testing Proves Efficacy and Safety • Reduced bacteria • Reduced somatic cell count • Increased protein content of milk 35+ Clinical and Field trials • Improved gut health • Reduced E.coli • Better maternal, piglet health • Improved performance • Reduced C. perfringens • Improved performance Strong C
Slide 14: Economics and Trial Results
Economics and Trial Results Benefits of OxC-beta: • Replace AGPs without losing Cost of OxC-beta: performance • Comparable to antibiotics (AGPs) • Outperforms other alternatives • Competitive to other alternatives • Effectiveness • Consistency • +ve impact on overall health Strong Competitive Advant
Slide 15: OxC-Beta for Companion Animal
OxC-Beta™ FOR COMPANION ANIMAL North America China, Taiwan & Mexico First Health Chews sales in • JV with Mimi’s Taiwan in April 2019, first Rock, forming sale to Pet Food new company manufacturer in Taiwan, Center Beach Feb 2020 First Health Chews sales in Chinese market in 2019 First Health Chews
Slide 16: OxC-beta for Human Wellness: Nutraceutical
OxC-beta™ FOR HUMAN WELLNESS: NUTRACEUTICAL Accelerating plans for commercial launch of its OxC-beta™ Technology for human use in response to COVID-19 Pandemic Hired Bloom Burton & Co.’s strategic Consultancy Group in order to optimize launch of the product into the US market Largest Global Opportun
Slide 17: Investment Summary
Investment Summary Proven solution to replace antibiotic use in animal feeds and help ensure livestock health Accelerating plans for commercial launch of OxC-beta™ as Nutraceutical Partnership with Mimi’s Rock (MIMI/TSXV) for Companion Animal product Growing Sales Pipeline; recurring revenue from re
Slide 18: Experienced Management & Board, Proven Track Record
Experienced Management & Board, Proven Track Record Kym Anthony Paul Mesburis CEO Director Jeffrey Kraws Dr. Graham Burton Chairman Director Aubrey Dan David Hankinson Director Director Industry Specific Knowledge and Success 18
Slide 19: Investor Presentation May 2020
Investor Presentation • May 2020 19